# Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT04102241** · PHASE2 · COMPLETED · sponsor: **Tianjin Hemay Pharmaceutical Co., Ltd** · enrollment: 216 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** 15mg Hemay005
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04102241
- **Lead sponsor:** Tianjin Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-30
- **Primary completion:** 2020-10-12
- **Final completion:** 2021-07-21
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04102241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04102241, "Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04102241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*